AILERON THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.77 USD | +2.17% |
|
-3.33% | +23.66% |
| May. 03 | Aileron Therapeutics Closes Direct Offering of Shares, Warrants | MT |
| May. 01 | Transcript : Aileron Therapeutics, Inc. - Special Call |
Presentation Operator MessageOperator (Operator)Greetings. Welcome to Aileron Therapeutics 202...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Aileron Therapeutics, Inc. is a biopharmaceutical company. The Company is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue, allowing for drainage of the pleural effusion. It has completed Phase Ib and Phase IIa clinical trials for the treatment of loculated pleural effusions.
Calendar
2024-08-06
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.77
USD
Average target price
19
USD
Spread / Average Target
+403.98%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.66% | 79.71M | |
| +8.63% | 114B | |
| +13.17% | 107B | |
| -12.76% | 22.22B | |
| -3.96% | 21.28B | |
| -7.19% | 17.51B | |
| -39.93% | 17.17B | |
| +6.67% | 14.14B | |
| +33.90% | 12.2B | |
| -28.60% | 7.83B |
- Stock Market
- Equities
- ALRN Stock
- News Aileron Therapeutics, Inc.
- Transcript : Aileron Therapeutics, Inc. - Special Call